Finoriq research workspace
aTYR PHARMA INC (ATYR) Company Overview
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of. Review ATYR filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
- Company
- aTYR PHARMA INC (ATYR)
- Ticker
- ATYR
- Market Cap
- $47.8M
- Latest Price
- $0.488
- Industry
- Biotech & Pharma
aTYR PHARMA INC (ATYR) Current Valuation Metrics
Static valuation preview for aTYR PHARMA INC (ATYR). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 302x | Revenue | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | -122.0% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -103.0% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 0.99x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.